Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBITDA Margin (2023 - 2025)

CG Oncology filings provide 3 years of EBITDA Margin readings, the most recent being 2097.33% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 624675.0% to 2097.33% in Q4 2025 year-over-year; TTM through Dec 2025 was 4722.13%, a 534512.0% increase, with the full-year FY2025 number at 4722.13%, up 534512.0% from a year prior.
  • EBITDA Margin hit 2097.33% in Q4 2025 for CG Oncology, up from 3068.97% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2097.33% in Q4 2025 to a low of 1935500.0% in Q4 2023.
  • Median EBITDA Margin over the past 3 years was 15817.53% (2024), compared with a mean of 228455.68%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 192715592bps in 2024 and later tumbled -7691409bps in 2025.
  • CG Oncology's EBITDA Margin stood at 1935500.0% in 2023, then skyrocketed by 100bps to 8344.08% in 2024, then skyrocketed by 75bps to 2097.33% in 2025.
  • The last three reported values for EBITDA Margin were 2097.33% (Q4 2025), 3068.97% (Q3 2025), and 81161.54% (Q1 2025) per Business Quant data.